Is There a Future for Biopharmaceutical Value-Based Contracting?

Published Apr 22, 2020

Value in Health Themed Section Offers Expanded Global Perspective

Value in HealthLawrenceville, NJ, USA—April 22, 2020—Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, announced today the publication of a series of articles providing perspectives on biopharmaceutical value-based contracting and what the future may hold for risk-sharing arrangements. The series was published in the April 2020 issue of Value in Health

“Value in healthcare is measured in terms of the patient outcomes achieved per dollars spent,” said Guest Editor Joshua P. Cohen, PhD, an independent consultant based in Boston, MA.“As such, when payers and policy makers measure the output of healthcare systems, it is not the volume of services delivered that matters, but rather the outcomes. Considering this, there has been an uptick in interest in value—or outcomes-based contracts. Nevertheless, in the United States there has been more talk than actual implementation of biopharmaceutical value-based contracts. In this themed section of Value in Health, 4 contributors provide balanced and sobering perspectives on value-based contracting and what the future may hold for risk-sharing arrangements.”

In his introductory editorial, “Is There a Future for Value-Based Contracting?,” Dr Cohen provides a historical perspective and introduces the other 4 articles in the series:

  1. Are Value-Based Arrangements the Answer We’ve Been Waiting for?,” by Robert W. Dubois, Kimberly Westrich, and Lisabeth Buelt
  2. Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead,” by Anna Kaltenboeck
  3. Managed Entry Agreements: Policy Analysis From the European Perspective,” by Monique Dabbous, Lylia Chachoua, Aleksandra Caban, and Mondher Toumi
  4. Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications,” by Michael Fralick, Joshua J. Gagne, Elisabetta Patorno, Raisa Levin, and Aaron S. Kesselheim

“Ultimately,” said Cohen, “better alignment of price and value of health technologies and medical services is the key objective of any healthcare system. This can be achieved through multiple means, including value-based arrangements; however, the scope of value-based arrangements is relatively narrow and the logistical hurdles, including data collection and reaching consensus on the terminology surrounding value across stakeholders, remain formidable.”


ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website  | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram

Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2018 impact factor score is 5.037. Value in Health is ranked 5th of 98 journals in healthcare sciences and services, 4th of 81 journals in health policy and services, and 11th of 363 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world.
Website  | Twitter (@isporjournals)

Related Stories

Proposed Drug Pricing Policy Would Save Medicare Between $1 Billion and $2.1 Billion Annually

Sep 5, 2023

Value in Health, the official journal of ISPOR, announced the publication of a report that identifies expensive Medicare Part B drugs with low added therapeutic benefit and models a reimbursement policy for them based on domestic reference pricing.

Global Multistakeholder Panel Provides First-of-its-Kind Guidance on Assessing the Value of Biosimilar Drugs

Aug 15, 2023

Value in Health published a new ISPOR Report that provides an overview of gaps and challenges in the value assessment of biosimilars and identifying potential approaches to address them. The report was published in the August 2023 issue of Value in Health.

ISPOR’s Value in Health Regional Issues Receives Its First Impact Factor Score

Aug 7, 2023

Value in Health Regional Issues, the regionally focused journal of ISPOR, received its first-ever impact factor score this year. Value in Health, one of the top-ranked journals in the HEOR field, maintained its high ranking on the prestigious list of scholarly journals.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now